Bicara Therapeutics (BCAX) Free Cash Flow (2023 - 2026)

Bicara Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$37.6 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 33.67% year-over-year to -$37.6 million; the TTM figure through Mar 2026 stood at -$116.6 million (down 31.97% YoY), while the FY2025 annual figure was -$107.1 million, down 43.16% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$37.6 million, down from -$24.1 million in the prior quarter.
• The five-year high for Free Cash Flow was -$8.5 million in Q4 2023, with the low at -$37.6 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$24.9 million (2025), against an average of -$22.8 million.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 254.96% in 2024, then advanced 19.78% in 2025.
• Bicara Therapeutics' Free Cash Flow stood at -$8.5 million in 2023, then plunged by 254.96% to -$30.1 million in 2024, then rose by 19.78% to -$24.1 million in 2025, then tumbled by 55.73% to -$37.6 million in 2026.
• Business Quant data shows BCAX's Free Cash Flow at -$37.6 million in Q1 2026, -$24.1 million in Q4 2025, and -$29.3 million in Q3 2025.